Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations
Menée à partir de données portant sur 1 768 enfants atteints d'une leucémie lymphoblastique aiguë (âge moyen : 6,7 ans), cette étude de cohorte évalue, en fonction de la présence de mutations sur les gènes TPMT et NUDT15, l'intérêt de réduire la dose de mercaptopurine pour limiter la toxicité du traitement
Background: Thiopurines such as mercaptopurine (MP) are widely used to treat acute lymphoblastic leukemia (ALL). Thiopurine-S-methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) inactivate thiopurines, and no-function variants are associated with drug-induced myelosuppression. Dose adjustment of MP is strongly recommended in patients with intermediate or complete loss of activity of TPMT and NUDT15. However, the extent of dosage reduction recommended for patients with intermediate activity in both enzymes is currently not clear. Methods: MP dosages during maintenance were collected from 1768 patients with ALL in Singapore, Guatemala, India, and North America. Patients were genotyped for TPMT and NUDT15, and actionable variants defined by Clinical Pharmacogenetics Implementation Consortium (CPIC) were used to classify patients as TPMT and NUDT15 normal metabolizers (TPMT/NUDT15 NM), TPMT or NUDT15 intermediate metabolizers (TPMT IM or NUDT15 IM), or TPMT and NUDT15 compound intermediate metabolizers (TPMT/NUDT15 IM/IM). In parallel, we evaluated MP toxicity, metabolism, and dose adjustment using a Tpmt/Nudt15 combined heterozygous mouse model (Tpmt +/-/Nudt15 +/-). Results: Twenty-two patients (1.2%) were TPMT/NUDT15 IM/IM in the cohort, with the majority self-reported as Hispanics (68.2%, 15/22). TPMT/NUDT15 IM/IM patients tolerated a median daily MP dose of 25.7 mg/m2 (interquartile range [IQR], 19.0-31.1 mg/m2), significantly lower than TPMT IM and NUDT15 IM dosage (P< .001). Similarly, Tpmt +/-/Nudt15 +/- mice displayed excessive hematopoietic toxicity and accumulated more metabolite (DNA-TG) than wildtype or single heterozygous mice, that was effectively mitigated by a genotype-guided dose titration of MP. Conclusion: We recommend more substantial dose reductions to individualize MP therapy and mitigate toxicity in TPMT/NUDT15 IM/IM patients.